Current asthma treatment recommendations are based on clinical trials demonstrating
improved clinical outcomes of combination ICS plus LABA over ICS alone. Whether LABA …

Background Long-acting β 2-agonists are recommended as add-on therapy to
antiinflammatory treatment in patients with chronic persistent asthma. Results from individual …

The combination of long-acting beta-agonist (LABA) bronchodilators with inhaled
corticosteroids (ICSs) has been shown to be an extremely effective treatment for asthma …

The use of a regular long-acting β 2-adrenoceptor agonists (β 2-agonists; LABA) is now
established in asthma guidelines as the preferred option for second-line controller therapy in …

Fixed-dose combinations of inhaled corticosteroids (ICSs) and long-acting β2-agonists
(LABAs) have been used to manage asthma for several years. They are the preferred …

Asthma treatment guidelines advocate the use of long-acting β2-agonists (LABA) in addition
to inhaled corticosteroids (ICS) in patients whose asthma is uncontrolled by ICS alone …

If asthma is not controlled with low-dose inhaled corticosteroids (ICS), by far the best next
step is the addition of a long-acting, inhaled beta-agonist (LABA). Questions regarding the …

Concerns about the safety of long-acting β2-agonist (LABA) therapy, has led to the
appearance of multiple publications and recommendations. This review critically examines …

Several studies suggested an association between the regular use of β 2-agonists and
asthma deaths. Whether this association represents adverse effects of β-agonist use or is …

BACKGROUND: Safety of long-acting beta agonists (LABA) has been questioned and
recent evidence suggested a detrimental effect on asthma control as well as an increased …